ERBB2 and breast cancer: We investigated the prognostic value of serum lipid control by treatment for dyslipidaemia in each breast cancer intrinsic subtypes, and in only patients with HR-positive/HER2-negative breast cancer, the good control group had significantly better RFS than the poor control group (p = 0.045, log-rank) (Supplement Figs. S5 and S6).